Richard Greil
Impact in
Papers in
- Co-authors
- Alexander EgleMichael GnantR. JakeszGabriel RinnerthalerSimon Peter GampenriederLisa PleyerInge TinhoferTanja Nicole Hartmann
- Journals
- Blood (99 papers)Journal of Clinical Oncology (98 papers)Annals of Oncology (46 papers)Cancer Research (24 papers)Annals of Hematology (15 papers)
- Partner nations
- AustriaGermanyUnited States
In The Last Decade
Richard Greil
702 papers receiving 19.7k citations
Hit Papers
Peers
Comparison fields: 5 of 158
- Oncology 10.9k
- Genetics 3.0k
- Cancer Research 3.9k
- Pathology and Forensic Medicine 4.2k
- Hematology 2.3k
Countries citing papers authored by Richard Greil
This map shows the geographic impact of Richard Greil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Greil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Greil more than expected).
Fields of papers citing papers by Richard Greil
This network shows the impact of papers produced by Richard Greil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Greil. The network helps show where Richard Greil may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Richard Greil, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 4 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 10 | |
| 9 | Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study Hit paper breakdown → | 2022 | 204 |
| 10 | 2021 | 1 | |
| 11 | 2020 | 37 | |
| 12 | 2018 | 32 | |
| 13 | 2017 | 79 | |
| 14 | 2016 | 12 | |
| 15 | 2013 | 298 | |
| 16 | 2012 | 58 | |
| 17 | 2012 | 32 | |
| 18 | 2010 | 18 | |
| 19 | 2009 | 66 | |
| 20 | 2008 | 148 |
About Richard Greil
Richard Greil is a scholar working on Genetics, Oncology, Hematology, Pathology and Forensic Medicine and Cancer Research, having authored 731 papers that have together received 20.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (154 papers), Chronic Lymphocytic Leukemia Research (144 papers), Cancer Treatment and Pharmacology (86 papers), Advanced Breast Cancer Therapies (77 papers), Breast Cancer Treatment Studies (76 papers), Colorectal Cancer Treatments and Studies (73 papers), Lung Cancer Treatments and Mutations (65 papers) and Multiple Myeloma Research and Treatments (58 papers). The work is most often cited by research in Oncology (10.9k citations), Genetics (3.0k citations), Cancer Research (3.9k citations), Pathology and Forensic Medicine (4.2k citations) and Hematology (2.3k citations). Richard Greil has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Alexander Egle, Michael Gnant, R. Jakesz, Gabriel Rinnerthaler, Simon Peter Gampenrieder, Lisa Pleyer, Inge Tinhofer, Tanja Nicole Hartmann, Thomas Melchardt and Brigitte Mlineritsch. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, Cancer Research and Annals of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.